CCL2 and Fabry disease: Mean plasmatic MCP-1 concentration (Figure 4) was significantly increased in plasma from FD patients compared to healthy controls (46.69 ± 3.96 ng/mL in controls and 60.08 ± 9.06 ng/mL in FD patients: in naïve 53.23 ± 4.70 ng/mL and in ERT-treated 65.22 ± 18.78 ng/mL).